 |
|
 
|
|
What DNDi Does
to Address Sleeping
Sickness
DNDi ’s HAT-specific portfolio balances short- and long-term objectives.
Sickness
Short term: better use of existing treatments and improved research capacity
• Nifurtimox-eflornithine combination therapy (NECT), a simplified treatment for stage 2 HAT
Long term: new drugs and improved research capacity across region
• Fexinidazole: first drug candidate in preclinical development from nitroimidazoles project
• New drugs developed from compounds identified in discovery research and progressed through HAT lead optimisation consortium
• Multi-country, multi-partner HAT Platform to strengthen regional research capacity
By 2014, DNDi aims to deliver from its HAT-specific portfolio:
• 1 new combination therapy recommended by WHO
• 1 new drug registered
• A robust pipeline
• Nifurtimox-eflornithine combination therapy (NECT), a simplified treatment for stage 2 HAT
Long term: new drugs and improved research capacity across region
• Fexinidazole: first drug candidate in preclinical development from nitroimidazoles project
• New drugs developed from compounds identified in discovery research and progressed through HAT lead optimisation consortium
• Multi-country, multi-partner HAT Platform to strengthen regional research capacity
By 2014, DNDi aims to deliver from its HAT-specific portfolio:
• 1 new combination therapy recommended by WHO
• 1 new drug registered
• A robust pipeline
Published by Drugs for Neglected Diseases Initiative - 15 Chemin Louis-Dunant 1202 Geneva Switzerland - Photo credits: DNDi unless otherwise stated - Editor: Sadia Kaenzig - Tel: +41 22 906 9230 - Fax: +41 22 906 9231 - www.DNDi.org